Elacestrant in Preoperative Setting, a Window of Opportunity Study
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
ELIPSE is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates
the effect of Elacestrant on proliferation after 4 weeks of treatment in postmenopausal women
with Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative
(HER2-negative) early breast cancer (BC) amenable to surgery.